Organized by the ENFSI, under the European Commission Grant “Forensic Fundamentals, Technology, Multidisciplinarity, Research, Evaluation (FOR-FUTURE)” ISF-2023-TF2-AG-ENFSI-IBA-2
Duration: 01/01/2026 – 31/12/2032
Major activity:
Building a European research and innovation ecosystem to respond efficiently to future health crises caused by infectious diseases by fostering a coordinated and efficient research landscape covering the whole spectrum of pandemic preparedness research including a EU-wide network of clinical research.
Role of the LNS:
Contribute to the work packages on (1) the alignment of research priorities, (2) an ever-warm research and innovation ecosystem for basic and preclinical research for pandemic preparedness and response and, (3) Public Health Research Networks.
Funding source:
co-funded by the European Union under Grant Agreement 101226682.
Project website:
Organized by European Union Drug Agency (EUDA)
ECDC-AURORAE: ECDC Framework contract to the consortium AURORAE: Support to microbiology-related activities and capacity building focusing on COVID-19 and influenza in the EU/EEA, the Western Balkans and Türkiye. Laboratory support, training, and standardisation”
Duration: 06/2022 – 2026
Major activity:
Strengthening the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training
Role of the LNS:
The LNS is part of the AURORAE Consortium and provides tailored training through a 5 day twinning visit on SARS-CoV-2 Sequencing and Bioinformatics.
Funding source:
Framework Contract for Services by the European Centre for Disease Prevention and Control to the AURORAE Consortium under framework contract number ECDC/2022/001
EIRENE, Infrastructure de recherche pour l’évaluation de l’exposition environnementale en Europe (2025 – permanent) :
EIRENE (https://eirene.eu/) aims to create new capacities for human exposome research and assessment of risks associated with environmental exposures by developing a network of harmonized laboratories, environmental studies, population cohorts, and databases. It will advance our understanding of the role of the exposome in the development of chronic disease. As such, EIRENE will play a key role in developing new strategies and interventions for protecting population health, preventing chronic diseases, and advancing precision medicine.
The LNS is the National Node Lead Institution for Luxembourg: in this role, we have included the accredited hospitals (CHL and CHEM), the Luxembourg National Data Service, and the research institutes (University of Luxembourg, Luxembourg Institute for Science and Technology, Luxembourg Institute of Health, and Luxembourg Institute of Socio-Economic Research).
Currently, the LNS Health Protection Department is running two surveys on the field :
1. The LëtzHBM survey in the general population:
LëtzHBM measures the exposure to chemical substances in the general population across Europe for chemicals that may pose a risk to health. This helps to develop appropriate policies to protect public health. In Luxembourg, the survey focuses on two age groups: children aged 6 to 11 years and adults aged 18 to 39 years. If you want to participate in the LëtzHBM survey, click here.
2. The Healthcare survey and the Waste management survey in the working population :
Ces enquêtes évaluent les niveaux d’exposition à des substances chimiques spécifiques à chaque secteur. Elles contribuent ainsi à l’élaboration de lignes directrices et de politiques visant à protéger la santé des travailleurs.
Participation via Clinical Genetics for the diagnosis and follow-up of patients with rare congenital anomalies and intellectual disabilities.
More information on https://ern-ithaca.eu/
Duration: 01/01/2024 – 31/12/2027
Major activity:
Support to Member States/Associated Countries in their efforts to develop and update their National Action Plan (NAP) on Antimicrobial Resistance (AMR)
Role of the LNS:
JAMRAI liaison for Member State engagement on One Health strategies, contribute to the national program for antimicrobial stewardship in human health, task leader for strengthening national surveillance systems in the human sector, participate in one health AMR surveillance.
Funding source:
co-funded by the European Commission under Grant Agreement 101127787
Project website:
Duration: 1/11/2023 – 31/10/2026
Major activity:
Enhance and improve national public health wastewater surveillance by strengthening knowledge exchange and best practices.
Role of the LNS:
Contribute as affiliated entity of the Luxembourg Institute of Science and Technology to the task on sequencing techniques and analysis.
Funding source:
co-funded by the European Union under Grant Agreement 101140460.
Website project:
Participation in the EU-wide initiative to foster collaboration among national cancer centers, harmonize diagnostic and treatment standards, and strengthen the integration of research and innovation in cancer care.
Funding source:
Website :
Participation in the research project “H.A.I.R. – Hair Drug Analysis In Recreational Settings in Luxembourg – Pilot Project”, jointly conducted by the Forensic Toxicology Department, the Luxembourg Focal Point of the European Union Drugs Agency (PFLAD), and 4motion asbl. The project explores the potential of hair analysis as a complementary tool for national drug monitoring in recreational settings.
AFR-funded projects investigating neuronal vulnerability and astrocyte alterations in Alzheimer’s and Parkinson’s disease.
Translational project on Alzheimer’s disease in collaboration with the LCSB and the University of Luxembourg, supported by the Fondation du Pélican.
CORE-funded project with LIST studying neuromelanin neuron degeneration in Parkinson’s disease using high-resolution microscopy.
PARC (Partnership for the Assessment of Risks from Chemicals), le Partenariat pour l’évaluation des risques liés aux substances chimiques (2022-2029) :
PARC (https://www.eu-parc.eu) aims to develop next-generation chemical risk assessment to protect human health and the environment. It supports the European Union’s Chemicals Strategy for Sustainability and the European Green Deal’s “Zero pollution” ambition with new data, knowledge, methods and tools, expertise and networks.
LNS is the Grant Signatory for Luxembourg: in this role, we have included the research institutes in Luxembourg as Affiliated Entities (University of Luxembourg, Luxembourg Institute for Science and Technology and Luxembourg Institute of Health).
The LNS is the permanent deputy in the Governing Board, together with the Health Directorate that is the principal representative for Luxembourg.
The LNS is strongly involved in the implementation of the PARC work plan, with a main focus on human biomonitoring and exposure assessment, innovative laboratory and sampling methods, health-based interpretation of monitoring data and integrative risk assessment.
The LNS has a leading role in several PARC projects:
« Beyond food: Organic contaminants in daily environment » ; « PFAS in breast milk and infant health » ; « Occupational Biomonitoring of emerging chemicals: A new approach » ; « Health-based guideline values for indoor air ».
Stakeholders are invited to join PARCopedia, the online knowledge management and community platform created in PARC, which is open to the whole community of professionals in chemical risk assessment.
Source de financement :
Development and validation of a method for the quantification of new psychoactive substances (NPS), particularly synthetic opioids, in blood using liquid chromatography–tandem mass spectrometry (LC-MS/MS).
Funding source:
Project funded by the ANR and the FNR, involving INRAE UMR 1319, INSERM U1220, the University of Luxembourg and the LNS.
Background
– Inflammatory bowel diseases (IBD) are recognized by the WHO as a major challenge for the 2030 Agenda for Sustainable Development.
– IBD are chronic inflammatory disorders of the gastrointestinal tract (GIT) that persist throughout a person’s lifetime and include Crohn’s disease (CD) and ulcerative colitis (UC). These debilitating conditions have a significant impact on patients’ quality of life.
– IBD are multifactorial gastrointestinal disorders. Existing therapeutic approaches have variable efficacy, and patients may develop treatment resistance.
Rationale and objectives
– The precise etiology of IBD remains unknown, with both genetic and environmental factors contributing to disease development. The gut microbiota has attracted increasing interest, highlighting the complex relationship between the host and the microbiota in the context of IBD pathogenesis.
The research hypothesis of RestorPro is that profiling inter-individual proteolytic variability can be used to stratify patients with IBD, and that restoring proteolytic homeostasis through the development of tailored serine protease inhibitors (serpins) could be used to treat intestinal inflammation.
RestorPro will open new avenues for the development of novel biomarkers and personalized therapies targeting proteolytic activity in IBD.
Collaboration in the development and validation of genomic screening tools to reduce time-to-diagnosis for rare diseases.
More information on https://www.screen4care.eu/
Major activity:
Network of virology laboratories, integrated in the project PROACT EU RESPONSE (funded by the European Union under Grant Agreement 101156304) to strengthen the existing clinical network by adding on-site operational laboratories.
Role of the LNS:
Conduct External Quality assessment and participate to the working group VIRVOLT.
Website project:
Project website:
Project website:
Project website:
HBM4EU – science and policy for a healthy future (2017-2022)
HBM4EU (https://www.hbm4eu.eu/) has been set-up to coordinate and advance human biomonitoring in Europe. The program has generated evidence of the actual exposure of citizens to chemicals and the possible health effects in order to support policy-making.
The LNS was the Grant Signatory for Luxembourg: in this role, we have included the research institutes in Luxembourg as Affiliated Entities (Luxembourg Institute for Science and Technology and Luxembourg Institute of Health).
The LNS was in charge of the human biomonitoring for Luxembourg. The results for the country have been integrated in the European Human Biomonitoring Dashboard and will be transferred later on in the Information Platform for Chemical Monitoring from the European Commission (IPCHEM, https://ipchem.jrc.ec.europa.eu/).
Website project :
Website project :
